Kayne Anderson Rudnick Investment Management
WST icon

Kayne Anderson Rudnick Investment Management’s West Pharmaceutical WST Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215M Sell
858,298
-96,851
-10% -$24.1M 0.63% 56
2025
Q4 		$263M Sell
955,149
-82,945
-8% -$22.7M 0.71% 53
2025
Q3 		$272M Sell
1,038,094
-13,236
-1% -$3.22M 0.66% 54
2025
Q2 		$230M Buy
1,051,330
+53,448
+5% +$11.4M 0.55% 61
2025
Q1 		$223M Buy
997,882
+365,575
+58% +$101M 0.55% 58
2024
Q4 		$207M Buy
632,307
+21,806
+4% +$6.86M 0.48% 69
2024
Q3 		$183M Buy
610,501
+16,809
+3% +$5.15M 0.4% 69
2024
Q2 		$196M Buy
593,692
+37,702
+7% +$13.3M 0.48% 67
2024
Q1 		$220M Buy
555,990
+110,413
+25% +$40.8M 0.51% 60
2023
Q4 		$157M Buy
445,577
+30,902
+7% +$10.9M 0.39% 75
2023
Q3 		$156M Sell
414,675
-71,135
-15% -$27.5M 0.44% 65
2023
Q2 		$186M Buy
485,810
+25,642
+6% +$9.16M 0.52% 60
2023
Q1 		$159M Buy
460,168
+23,411
+5% +$6.84M 0.47% 62
2022
Q4 		$103M Buy
436,757
+124,874
+40% +$29.6M 0.32% 88
2022
Q3 		$76.7M Buy
311,883
+23,334
+8% +$7.11M 0.25% 108
2022
Q2 		$87.2M Buy
288,549
+4,399
+2% +$1.43M 0.28% 101
2022
Q1 		$117M Buy
284,150
+14,823
+6% +$5.8M 0.31% 97
2021
Q4 		$126M Sell
269,327
-91,934
-25% -$39.6M 0.29% 99
2021
Q3 		$153M Buy
361,261
+18,616
+5% +$7.85M 0.37% 85
2021
Q2 		$123M Buy
342,645
+74,247
+28% +$24.5M 0.3% 99
2021
Q1 		$75.6M Buy
268,398
+21,160
+9% +$6.06M 0.2% 117
2020
Q4 		$70M Buy
247,238
+13,468
+6% +$3.78M 0.2% 116
2020
Q3 		$64.3M Buy
233,770
+14,748
+7% +$3.9M 0.23% 104
2020
Q2 		$49M Buy
219,022
+14,974
+7% +$2.94M 0.2% 106
2020
Q1 		$31.1M Buy
204,048
+9,885
+5% +$1.52M 0.18% 111
2019
Q4 		$29.2M Buy
194,163
+19,293
+11% +$2.81M 0.14% 127
2019
Q3 		$24.8M Buy
174,870
+12,380
+8% +$1.7M 0.13% 122
2019
Q2 		$20.3M Buy
162,490
+20,272
+14% +$2.39M 0.11% 132
2019
Q1 		$15.7M Buy
142,218
+13,549
+11% +$1.41M 0.09% 136
2018
Q4 		$12.6M Buy
128,669
+26,425
+26% +$2.87M 0.09% 143
2018
Q3 		$12.6M Buy
102,244
+15,049
+17% +$1.69M 0.07% 158
2018
Q2 		$8.66M Buy
87,195
+42,949
+97% +$3.95M 0.06% 178
2018
Q1 		$3.91M Buy
44,246
+7,771
+21% +$727K 0.03% 209
2017
Q4 		$3.6M Buy
36,475
+1,536
+4% +$151K 0.03% 214
2017
Q3 		$3.36M Buy
34,939
+419
+1% +$37.9K 0.03% 214
2017
Q2 		$3.26M Buy
34,520
+3,560
+11% +$327K 0.03% 216
2017
Q1 		$2.53M Buy
30,960
+4,787
+18% +$400K 0.03% 236
2016
Q4 		$2.22M Buy
26,173
+5,099
+24% +$401K 0.03% 245
2016
Q3 		$1.57M Buy
+21,074
New +$1.67M 0.02% 261

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's WST Position: Q1 2026 in Review

Kayne Anderson Rudnick Investment Management reduced its West Pharmaceutical (WST) stake by 10% in Q1 2026, selling an estimated $24.1M and leaving 858,298 shares worth $215M. The position accounts for 0.63% of the portfolio, ranked #56.

Kayne Anderson Rudnick Investment Management first reported a position in WST in Q3 2016 and has held it in 39 quarters since. The position peaked at $272M in Q3 2025. 754 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Kayne Anderson Rudnick Investment Management held 858,298 shares of West Pharmaceutical worth $215M as of Q1 2026.
  • Kayne Anderson Rudnick Investment Management sold 96,851 West Pharmaceutical shares in Q1 2026, an estimated $24.1M.
  • West Pharmaceutical made up 0.63% of Kayne Anderson Rudnick Investment Management's portfolio in Q1 2026, its #56 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in West Pharmaceutical in Q3 2016 and has held it in 39 quarters since.
  • Kayne Anderson Rudnick Investment Management's West Pharmaceutical position peaked at $272M in Q3 2025.
  • 754 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2026, filed 14 May 2026.